Antibody-Drug Conjugates

Earendil Labs and WuXi Biologics Forge Strategic Alliance to Fast-Track Bispecific, Multispecific Antibodies, and ADCs

by
Microscopic view of bispecific antibodies and ADCs targeting cancer cells in a laboratory setting

“Earendil Labs, an AI-powered innovator in next-generation biologics, has partnered with WuXi Biologics, a leading global CRDMO, to advance multiple pipeline candidates including bispecific and multispecific antibodies as well as antibody-drug conjugates (ADCs) targeting cancer, autoimmune diseases, and other serious conditions. The deal leverages WuXi’s comprehensive development and GMP manufacturing expertise to speed up timelines, … Read more

Iksuda Therapeutics Showcases Encouraging Phase 1 Results for IKS014 in HER2+ Oesophageal Cancer

by
Conceptual illustration of antibody-drug conjugate targeting HER2-positive cancer cells in the esophagus

“Iksuda Therapeutics is set to highlight preliminary data from its Phase 1 trial of IKS014, a HER2-targeted antibody-drug conjugate, at the ASCO Gastrointestinal Cancers Symposium. The analysis reveals an 80% clinical benefit rate in pretreated patients with advanced HER2+ oesophageal cancer, underscoring potential advancements in treating this challenging malignancy.” Study Overview Iksuda Therapeutics, a UK-based … Read more